Oral squamous cell carcinoma. Malignant neoplasm of mouth, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Surgery and Atorvastatin, 40 mg pill, C33H35FN2O5, daily, for 1 month, swallowing with water. Intervention 2: Control group: Surgery.
Sponsors
Karaj University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with oral squamous cell carcinoma Lack of any other cancer except for oral squamous cell carcinoma Not using any medication other than the ones prescribed by the surgeon No drug interaction with atorvastatin if taken concurrently with another medication Biopsy result of the patient indicates squamous cell carcinoma of the oral mucosa Having similar histopathology grades Ability to personally provide written informed consent or to understand and collaborate throughout the study
Exclusion criteria
Exclusion criteria: Inability or unwillingness to comply with study requirements Patients who were previously taking statins for any reason Treatment approach for oral squamous cell carcinoma varies due to its unique challenges Patients undergoing treatment with anti-HIV drugs Having a history of other cancers Smoker patients Patients who are consumers of a specific medication Patients with specific systemic diseases Patients with a history of intolerance to statins Patients with acute liver failure Pregnant and lactating women consumption of another drug that interacts with atorvastatin consumption of Gemfibrozil medication consumption of Clarithromycin medication consumption of Cyclosporine medication consumption of Itraconazole medication consumption of Colchicine medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Superoxide dismutase marker in the saliva. Timepoint: At the beginning of the study and 1 month after taking the drug. Method of measurement: The variable measurement (Superoxide Dismutase marker) in saliva is performed by qRT-PCR method in the laboratory.;Angiogenesis Factors in the Saliva. Timepoint: At the beginning of the study and 1 month after taking the drug. Method of measurement: The measurement of variables (Angiogenesis Factors) in saliva is carried out using the qRT-PCR method in the laboratory.;Beta-2 microglobulin Factor in the saliva. Timepoint: At the beginning of the study and 1 month after taking the drug. Method of measurement: The measurement of variables (Beta-2 microglobulin Factor) in saliva is carried out using the qRT-PCR method in the laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Arezoo Aghakouchakzadeh
Karaj University of Medical Sciences
Outcome results
None listed